雙調(diào)蛋白(AREG)活性蛋白
Active Amphiregulin (AREG)
AR; CRDGF; SDGF; Colorectum Cell-Derived Growth Factor; Schwannoma-Derived Growth Factor
- 編號(hào)APA006Hu01
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 90%
- 等電點(diǎn)5.1
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 1152 ¥ 2880 ¥ 5760 ¥ 17280 ¥ 43200
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
活性實(shí)驗(yàn)
Amphiregulin (AREG) is a well-characterized member of the epidermal growth factor (EGF) family and is one of the ligands of the EGF receptor (EGFR). AREG plays a key role in mammalian development and in the control of branching morphogenesis in various organs. Furthermore, AREG participates in a wide range of physiological and pathological processes activating the major intracellular signalling cascades governing cell survival, proliferation and motility. Besides, EGF has been identified as an interactor of AREG, thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human AREG and recombinant rat EGF. Briefly, AREG was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to EGF-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-AREG pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 μL stop solution to the wells and read at 450/630 nm immediately. The binding activity of recombinant human AREG and recombinant rat EGF was shown in Figure 1, the EC50?for this effect is 0.1 ug/mL.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過一個(gè)月,-80°C不超過12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲(chǔ),損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
APA006Hu01 | 雙調(diào)蛋白(AREG)活性蛋白 | Cell?culture;?Activity?Assays. |
RPA006Hu01 | 雙調(diào)蛋白(AREG)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA006Hu01 | 雙調(diào)蛋白(AREG)多克隆抗體 | WB; IHC; ICC; IP. |
MAA006Hu23 | 雙調(diào)蛋白(AREG)單克隆抗體 | WB; IHC; ICC; IP. |
MAA006Hu25 | 雙調(diào)蛋白(AREG)單克隆抗體 | WB; IHC; ICC; IP. |
MAA006Hu22 | 雙調(diào)蛋白(AREG)單克隆抗體 | WB; IHC |
MAA006Hu24 | 雙調(diào)蛋白(AREG)單克隆抗體 | WB; IHC; ICC/IF |
MAA006Hu26 | 雙調(diào)蛋白(AREG)單克隆抗體 | WB; IHC |
MAA006Hu21 | 雙調(diào)蛋白(AREG)單克隆抗體 | WB; IHC; ICC; IP. |
MAA006Hu27 | 雙調(diào)蛋白(AREG)單克隆抗體 | WB; IHC; ICC; IP. |
MAA006Hu29 | 雙調(diào)蛋白(AREG)單克隆抗體 | WB; IHC; ICC; IP. |
LAA006Hu76 | 雙調(diào)蛋白(AREG)單克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
SEA006Hu | 雙調(diào)蛋白(AREG)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
SCA006Hu | 雙調(diào)蛋白(AREG)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
LMA006Hu | 雙調(diào)蛋白(AREG)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
PSA006Hu01 | 雙調(diào)蛋白(AREG)抗體對(duì) | ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays. |
KSA006Hu01 | 雙調(diào)蛋白(AREG)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Onkologie | Amphiregulin and Epiregulin Expression in Colorectal Carcinoma and the Correlation with Clinicopathological Characteristics [Karger: 315380] |
Br J Cancer. | Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer. [Pubmed:24800946] |
Cancer Sci | Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer [PubMed: 25707609] |
J Cancer Res Clin Oncol | Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer [PubMed: 26195282] |
Oncotarget.? | Serum?level?of?hepatocyte?growth?factor?is a?novel?marker?of?predicting?theoutcome?and?resistance?to the?treatment?with?trastuzumab?in HER2-positive patients with metastatic gastric cancer [Pubmed:26716644] |
Acta?Pharmacologica Sinica | Anti-asthmatic activity of alkaloid compounds from Pericarpium Citri Reticulatae (Citrus reticulata 'Chachi') [Pubmed: 19363516] |
International Journal of Biological Sciences | CD9 regulates keratinocyte migration by negatively modulating the sheddase activity of ADAM17 [] |
Neoplasia | Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine [Pubmed: 33212364] |
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE | Polarization of ADAM17‐driven EGFR signalling in electric field‐guided collective migration of epidermal sheets [Pubmed: 33164313] |